What is the rationale for short-course preoperative radiotherapy in rectal cancer?

Short-Course Radiation in Rectal Cancer: Rationale and Clinical Application

Short-course preoperative radiotherapy (SCPRT) delivers 25 Gy in 5 fractions over one week and is a validated alternative to long-course chemoradiotherapy for intermediate-risk rectal cancer, offering equivalent local control and survival with lower acute toxicity, reduced treatment time, and cost-effectiveness. 1

Primary Rationale for SCPRT

Efficacy in Local Control and Survival

• SCPRT significantly reduces local recurrence rates compared to surgery alone, with 5-year local control rates of 91-94% when combined with total mesorectal excision (TME). 1, 2, 3
• The Swedish Rectal Cancer Trial demonstrated both survival advantage and decreased local recurrence with SCPRT versus surgery alone. 1
• Long-term follow-up (10-year) showed improved survival in stage III disease with negative circumferential resection margin (CRM) (50% vs 40%, p=0.032). 1

Equivalent Outcomes to Long-Course Chemoradiotherapy

• Direct comparison trials show no differences in local recurrence or overall survival between SCPRT and long-course chemoradiotherapy in unselected T3/T4 or node-positive patients. 1
• The Polish trial (312 patients) and Australian/New Zealand TROG 01.04 trial (326 patients) both confirmed equivalent oncological outcomes between short-course and long-course approaches. 1

Toxicity Profile Advantages

• SCPRT demonstrates significantly lower acute toxicity compared to long-course chemoradiotherapy, with fewer serious adverse events during treatment (0% vs 5.6% radiation dermatitis, p=0.003). 1
• Severe RT-induced toxicity occurs in only 1-5.4% of patients acutely and 7.6-10% experience late Grade 3 toxicity, which is acceptable. 2, 3
• Preoperative treatment is more effective and less toxic than postoperative treatment in all scenarios. 1

Clinical Indications for SCPRT

Intermediate-Risk Disease (Primary Indication)

• SCPRT is recommended for intermediate-risk rectal cancer: most cT3 with MRI-negative mesorectal fascia (mrf-), cN1-2, extramural vascular invasion (EMVI+), limited cT4a, and very low cT2 tumors. 1
• For resectable cancers where surgery will achieve clear CRM without downstaging, SCPRT provides excellent local control without the need for tumor regression. 1

Advanced Disease in Specific Populations

• In elderly patients (≥80-85 years) or those with severe comorbidities unable to tolerate chemoradiotherapy, SCPRT with delayed surgery (8 weeks) is an appropriate option. 1
• SCPRT with delayed surgery allows for tumor downstaging (44.9% vs 60.7% stage 0-II post-treatment, p<0.001) while maintaining low toxicity. 4

When NOT to Use SCPRT

• Locally advanced rectal cancer with threatened or involved CRM (cT3 mrf+, cT4b) requires long-course chemoradiotherapy (50.4 Gy with concurrent 5-FU) to achieve downstaging for R0 resection. 1
• When tumor downsizing is critical for sphincter preservation or organ preservation strategies, long-course chemoradiotherapy is preferred. 1

Practical Advantages

Treatment Efficiency

• SCPRT is completed in one week versus 5-6 weeks for long-course treatment, offering significant patient convenience and reduced healthcare costs. 1, 5
• Surgery is performed within 10 days of completing SCPRT (immediate surgery protocol), allowing rapid progression to definitive treatment. 1

Surgical Outcomes

• SCPRT does not increase postoperative complications compared to surgery alone, with equivalent rates of anastomotic leak (5% vs 6.6%), wound infection, and delayed ileus. 6
• Low anterior resection with sphincter preservation is achievable in appropriately selected patients. 6

Important Caveats and Limitations

Long-Term Toxicity Concerns

• Long-term follow-up reveals increased risk of secondary malignancies (14% vs 9%) and gastrointestinal complications including bowel obstruction requiring hospitalization. 1
• This negates survival advantage in node-negative populations, making patient selection critical. 1

Delayed Surgery Option

• SCPRT with delayed surgery (4-8 weeks) is a validated alternative that allows tumor regression (74% show signs on MRI reassessment) while maintaining low toxicity (5.4% severe RT toxicity). 1, 4
• Pathological complete response occurs in 8-11.9% with delayed surgery, compared to minimal rates with immediate surgery. 2, 4

Current Guideline Positioning

• The 2024 ASCO guideline recommends neoadjuvant long-course chemoradiotherapy over short-course RT in the context of total neoadjuvant therapy (TNT), though acknowledges SCRT may be viable depending on circumstances. 1
• ESMO 2017 guidelines state that either SCPRT or long-course chemoradiotherapy can be administered for intermediate-risk disease when CRM is not threatened. 1